



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

March 25, 2025

Timothy Noyes  
Chief Executive Officer  
Aerovate Therapeutics, Inc.  
930 Winter Street, Suite M-500  
Waltham, MA 02451

**Re: Aerovate Therapeutics, Inc.  
Amendment No. 4 to Registration Statement on Form S-4  
Exhibit Nos. 10.16, 10.17, 10.18, 10.19 and 10.20  
Filed March 24, 2025  
File No. 333-283562**

Dear Timothy Noyes:

We have concluded our assessment of your redacted exhibits for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Edwin M. O'Connor, Esq.

